200 related articles for article (PubMed ID: 15286662)
21. Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease.
Herrera GA; Teng J; Turbat-Herrera EA; Zeng C; Del Pozo-Yauner L
Kidney Int Rep; 2020 Nov; 5(11):1870-1893. PubMed ID: 33163710
[TBL] [Abstract][Full Text] [Related]
22. Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis.
Vora M; Kevil CG; Herrera GA
Ultrastruct Pathol; 2017; 41(5):358-368. PubMed ID: 28796568
[TBL] [Abstract][Full Text] [Related]
23. Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis.
Herrera GA; Turbat-Herrera EA; Teng J
Nephron; 2016; 132(2):119-36. PubMed ID: 26794829
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary light chain deposition disease: report of five cases and review of the literature.
Bhargava P; Rushin JM; Rusnock EJ; Hefter LG; Franks TJ; Sabnis SG; Travis WD
Am J Surg Pathol; 2007 Feb; 31(2):267-76. PubMed ID: 17255772
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Mohan M; Buros A; Mathur P; Gokden N; Singh M; Susanibar S; Jo Kamimoto J; Hoque S; Radhakrishnan M; Matin A; Davis C; Grazziutti M; Thanendrarajan S; van Rhee F; Zangari M; Davies F; Morgan G; Epstein J; Barlogie B; Schinke C
Am J Hematol; 2017 Aug; 92(8):739-745. PubMed ID: 28383130
[TBL] [Abstract][Full Text] [Related]
26. Renal monoclonal immunoglobulin deposition disease: the disease spectrum.
Lin J; Markowitz GS; Valeri AM; Kambham N; Sherman WH; Appel GB; D'Agati VD
J Am Soc Nephrol; 2001 Jul; 12(7):1482-1492. PubMed ID: 11423577
[TBL] [Abstract][Full Text] [Related]
27. Association light chain deposition disease (LCDD) and amyloidosis. One case.
Hofmann-Guilaine C; Nochy D; Jacquot C; Tricottet V; Bariety J; Camilleri JP
Pathol Res Pract; 1985 Aug; 180(2):214-9. PubMed ID: 3932985
[TBL] [Abstract][Full Text] [Related]
28. [The kidney in multiple myeloma. The physiopathological and clinical aspects].
Vivaldi P; Comotti C; Pedrazzoli M
Recenti Prog Med; 1994 Feb; 85(2):123-33. PubMed ID: 8184190
[TBL] [Abstract][Full Text] [Related]
29. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both.
Zand L; Nasr SH; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Kumar S; Kyle RA; Fervenza FC; Sethi S; Dingli D; Rajkumar SV; Kapoor P; McCurdy A; Leung N
Leuk Lymphoma; 2015; 56(12):3357-64. PubMed ID: 25860232
[TBL] [Abstract][Full Text] [Related]
30. An in vitro model of light chain deposition disease.
Keeling J; Herrera GA
Kidney Int; 2009 Mar; 75(6):634-45. PubMed ID: 18923384
[TBL] [Abstract][Full Text] [Related]
31. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J
Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
[TBL] [Abstract][Full Text] [Related]
32. Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy.
Gokden N; Cetin N; Colakoglu N; Kumar J; Abul-Ezz S; Barlogie B; Liapis H; Walker PD
Ultrastruct Pathol; 2007; 31(2):141-9. PubMed ID: 17613994
[TBL] [Abstract][Full Text] [Related]
33. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.
Pozzi C; D'Amico M; Fogazzi GB; Curioni S; Ferrario F; Pasquali S; Quattrocchio G; Rollino C; Segagni S; Locatelli F
Am J Kidney Dis; 2003 Dec; 42(6):1154-63. PubMed ID: 14655186
[TBL] [Abstract][Full Text] [Related]
34. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
35. Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.
Vidal R; Goñi F; Stevens F; Aucouturier P; Kumar A; Frangione B; Ghiso J; Gallo G
Am J Pathol; 1999 Dec; 155(6):2009-17. PubMed ID: 10595931
[TBL] [Abstract][Full Text] [Related]
36. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells.
Li M; Hering-Smith KS; Simon EE; Batuman V
Nephrol Dial Transplant; 2008 Mar; 23(3):860-70. PubMed ID: 17933841
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta.
Zhu L; Herrera GA; Murphy-Ullrich JE; Huang ZQ; Sanders PW
Am J Pathol; 1995 Aug; 147(2):375-85. PubMed ID: 7639331
[TBL] [Abstract][Full Text] [Related]
38. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.
Lavatelli F; Imperlini E; Orrù S; Rognoni P; Sarnataro D; Palladini G; Malpasso G; Soriano ME; Di Fonzo A; Valentini V; Gnecchi M; Perlini S; Salvatore F; Merlini G
FASEB J; 2015 Nov; 29(11):4614-28. PubMed ID: 26220173
[TBL] [Abstract][Full Text] [Related]
39. [The clinicopathological features of early renal amyloidosis].
Wang SX; Zou WZ; Wang M; E J; Wang SH; Tang XY
Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):120-3. PubMed ID: 12839672
[TBL] [Abstract][Full Text] [Related]
40. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
